Physiological and subjective effects of acute intranasal methamphetamine during extended-release alprazolam maintenance

Drug and Alcohol Dependence

Volumn 119, Issue 3, 2011, Pages 187-193

  Lile, Joshua A ^a   Stoops, William W ^a,b   Glaser, Paul E A ^a   Hays, Lon R ^a,c   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alprazolam; Benzodiazepine; Human; Methamphetamine; Pharmacotherapy; Subjective effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; METHAMPHETAMINE; PLACEBO;

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TACHYCARDIA;

ADMINISTRATION, INTRANASAL; ADULT; AFFECT; ALPRAZOLAM; AMPHETAMINE-RELATED DISORDERS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE;

EID: 82555192458     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.06.006     Document Type: Article

References (55)

1. Barrett A.C., Negus S.S., Mello N.K., Caine S.B. Effect of GABA agonists and GABA-A receptor modulations on cocaine- and food-maintained responding and cocaine discrimination in rats. J. Pharmacol. Exp. Ther. 2005, 315:858-871.
2. Baumann M.H., Gendron T.M., Becketts K.M., Henningfield J.E., Gorelick D.A. Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Biol. Psychiatry 1995, 38:751-755.
3. Collins S.L., Levin F.R., Foltin R.W., Kleber H.D., Evans S.M. Response to cocaine, alone and in combination with methylphenidate, in cocaine abusers with ADHD. Drug Alcohol Depend. 2006, 82:158-167.
4. Cruickshank C.C., Dyer K.R. A review of the clinical pharmacology of methamphetamine. Addiction 2009, 104:1085-1099.
5. DeSouza E.B. Neuroendocrine effects of benzodiazepines. J. Psychiatr. Res. 1990, 24(Suppl. 2):111-119.
6. Dewey S.L., Chaurasia C.S., Chen C.E., Volkow N.D., Clarkson F.A., Porter S.P., Straughter-Moore R.M., Alexoff D.L., Tedeshi D., Russo N.B., Fowler J.S., Brodie GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 1997, 25:393-398.
7. Druhan J.P., Fibiger H.C., Phillips A.G. Influence of some drugs of abuse on the discriminative stimulus properties of amphetamine. Behav. Pharmacol. 1991, 2:391-403.
8. Elkashef A., Vocci F., Hanson G., White J., Wickes W., Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst. Abuse 2008, 29:31-49.
9. Gatch M.B., Selvig M., Forster M.J. GABAergic modulation of the discriminative-stimulus effects of methamphetamine. Behav. Pharmacol. 2005, 16:261-266.
10. Giorgetti M., Javaid J.I., Davis J.M., Costa E., Guidotti A., Appel S.B., Brodie M.S. Imidazenil, a positive allosteric GABAA receptor modulator, inhibits the effects of cocaine on locomotor activity and extracellular dopamine in the nucleus accumbens shell without tolerance liability. J. Pharmacol. Exp. Ther. 1998, 287:58-66.
11. Goeders N.E. Cocaine differentially affects benzodiazepine receptors in discrete regions of the rat brain: persistence and potential mechanisms mediating these effects. J. Pharmacol. Exp. Ther. 1991, 259:574-581.
12. Goeders J.E., Goeders N.E. Effects of oxazepam on methamphetamine-induced conditioned place preference. Pharmacol. Biochem. Behav. 2004, 78:185-188.
13. Goeders N.E., McNulty M.A., Guerin G.F. Effects of alprazolam on intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 1993, 44:471-474.
14. Goeders N.E., McNulty M.A., Mirkis S., McAllister K.H. Chlordiazepoxide alters intravenous cocaine self-administration. Pharmacol. Biochem. Behav. 1989, 33:859-866.
15. Haney M., Rubin E., Foltin R.W. Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology 2011, (Epub ahead of print, PMID: 21373790).
16. Harris D.S., Boxenbaum H., Everhart E.T., Sequeira G., Mendelson J.E., Jones R.T. The bioavailability of intranasal and smoked methamphetamine. Clin. Pharmacol. 2003, 74:475-486.
17. Hart C.L., Gunderson E.W., Perez A., Kirkpatrick M.G., Thurmond A., Comer S.D., Foltin R.W. Acute physiological and behavioral effects of intranasal methamphetamine in humans. Neuropsychopharmacology 2008, 33:1847-1855.
18. Johanson C.E., Lundahl L.H., Schubiner H. Effects of oral cocaine on intravenous cocaine discrimination in humans. Exp. Clin. Psychopharmacol. 2007, 15:219-227.
19. Kaplan G.B., Greenblatt D.J., Ehrenberg B.L., Goddard J.E., Harmatz J.S., Shader R.I. Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. J. Clin. Pharmacol. 1998, 38:14-21.
20. Karila L., Weinstein A., Aubin H.J., Benyamina A., Reynaud M., Batki S.L. Pharmacological approaches to methamphetamine dependence: a focused review. Br. J. Clin. Pharmacol. 2010, 69:578-592.
21. Kelly T.H., Foltin R.W., Serpick E., Fischman M.W. Behavioral effects of alprazolam in humans. Behav. Pharmacol. 1997, 8:47-57.
22. 9-THC. Drug Alcohol Depend. 2011, 116:86-92.
23. Lile J.A., Stoops W.W., Glaser P.E., Hays L.R., Rush C.R. Discriminative-stimulus, subject-subject rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. J. Psychopharmacol. 2010, (Epub ahead of print, PMID: 20952456).
24. Lile J.A., Stoops W.W., Hays L.R., Rush C.R. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am. J. Drug Alcohol Abuse 2008, 34:721-729.
25. Lile J.A., Stoops W.W., Vansickel A.R., Glaser P.E., Hays L.R., Rush C.R. Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology 2005, 30:2103-2114.
26. A receptor subunit expression. Brain Res. 2000, 882:139-148.
27. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987, 334:1-100.
28. Lipton J.W., Ellison G.D. Continuous cocaine induces persisting changes in behavioral responsivity to both scopolamine and diazepam. Neuropsychopharmacology 1992, 7:143-148.
29. McGregor C., Srisurapanont M., Jittiwutikarn J., Laobhripatr S., Wongtan T., White J.M. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005, 100:1320-1329.
30. Mendelson J.H., Mello N.K., Teoh S.K., Ellingboe J., Cochin J. Cocaine effects on pulsatile secretion of anterior pituitary, gonadal and adrenal hormones. J. Clin. Endocrinol. Metab. 1989, 69:1256-1260.
31. Myers J.A., Earnest M.P. Generalized seizures and cocaine abuse. Neurology 1984, 34:675-676.
32. Negus S.S., Mello N.K., Fivel P.A. Effects of GABA agonists and GABA-A receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacology (Berl.) 2000, 152:398-407.
33. Nicosia N., Reardon E., Lorenz K., Lynn J., Buntin M.B. The Medicare hospice payment system: a consideration of potential refinements. Health Care Financ. Rev. 2009, 30:47-59.
34. Oliveto A.H., Bickel W.K., Hughes J.R., Shea P.J., Higgins S.T., Fenwick J.W. Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J. Pharmacol. Exp. Ther. 1992, 261:885-894.
35. Peris J. Repeated cocaine injections decrease the function of striatal gamma-aminobutyric acid(A) receptors. J. Pharmacol. Exp. Ther. 1996, 276:1002-1008.
36. Rush C.R., Stoops W.W., Hays L.R. Cocaine effects during d-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend. 2009, 99:261-271.
37. Rush C.R., Stoops W.W., Lile J.A., Glaser P.E., Hays L.R. Subjective and physiological effects of acute and intranasal methamphetamine during d-amphetamine maintenance. Psychopharmacology (Berl.) 2011, 214:665-674.
38. Rush C.R., Stoops W.W., Sevak R.J., Hays L.R. Cocaine choice in humans during d-amphetamine maintenance. J. Clin. Psychopharmacol. 2010, 30:152-159.
39. Rush C.R., Stoops W.W., Wagner F.P., Hays L.R., Glaser P.E. Alprazolam attenuates the behavioral effects of d-amphetamine in humans. J. Clin. Psychopharmacol. 2004, 24:410-420.
40. Rush C.R., Vansickel A.R., Lile J.A., Stoops W.W. Evidence-based treatment of amphetamine dependence: behavioral and pharmacological approaches. The Pharmacology and Treatment of Substance Abuse Using Evidence and Outcomes Based Perspectives 2010, Lawrence Erlbaum Associates, Mahwah, NJ. L. Cohen, F.L. Collins, A.M. Young, D.E. McChargue, T.R. Leffingwell (Eds.).
41. Schmitz J.M., Stotts A.L., Rhoades H.M., Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict. Behav. 2001, 26:167-180.
42. Seidel W.F., Cohen S.A., Wilson L., Dement W.C. Effects of alprazolam and diazepam on the daytime sleepiness of non-anxious subjects. Psychopharmacology (Berl.) 1985, 87:194-197.
43. Sommers I., Baskin D., Baskin-Sommers A. Methamphetamine use among young adults: health and social consequences. Addict. Behav. 2006, 31:1469-1476.
44. Stoops W.W., Lile J.A., Glaser P.E., Rush C.R. A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug Alcohol Depend. 2006, 84:206-209.
45. Stoops W.W., Lile J.A., Lofwall M.R., Rush C.R. The safety, tolerability and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance. Am. J. Drug Alcohol Abuse 2007, 33:769-776.
46. Stoops W.W., Rush C.R. Differential effects in humans after repeated administrations of zolpidem and triazolam. Am. J. Drug Alcohol Abuse 2003, 29:281-299.
47. Substance Abuse and Mental Health Services Administration, 2009. Treatment Episode Data Set (TEDS) Highlights - 2007 National Admissions to Substance Abuse Treatment Services. OAS Series #S-45, HHS Publication no. (SMA) 09-4360, Rockville, MD.
48. Suzuki T., Abe S., Yamaguchi M., Baba A., Hori T., Shiraishi H., Ito T. Effects of cocaine administration on receptor binding and subunits mRNA of GABA(A)-benzodiazpine receptor complexes. Synapse 2000, 38:98-215.
49. United Nations Office on Drugs and Crime World Drug Report 2009 2009, United Nations, Vienna, pp. 9-21.
50. Vocci F.J., Appel N.M. Approaches to the development of medications for the treatment of methamphetamine dependence. Addiction 2007, 102:96-106.
51. Volkow N.D., Wang G.J., Fowler J.S., Hizemann R., Gatley S.J., Dewey S.S., Pappas N. Enhanced sensitivity to benzodiazepines in active cocaine-abusing subjects: a PET study. Am. J. Psychiatry 1998, 155:200-206.
52. Washton A.M., Tatarsky A. Adverse effects of cocaine abuse. NIDA Res. Monogr. 1984, 49:247-254.
53. Weerts E.M., Froestl W., Griffiths R.R. Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug Alcohol Depend. 2005, 80:369-376.
54. Winhusen T., Somoza E., Singal B.M., Harrer J., Apparaju S., Mezinskis J., Desai P., Elkashef A., Chiang C.N., Horn P. Methylphenidate and cocaine: a placebo-controlled drug interaction study. Pharmacol. Biochem. Behav. 2006, 85:29-38.
55. Yoo J.H., Lee H.K., Kim H.C., Lee S.Y., Jang C.G. GABA(A) receptors mediate the attenuating effects of a 5-HT(3) receptor antagonist on methamphetamine-induced behavioral sensitization in mice. Synapse 2010, 64:274-279.